Investor Ideas #Potcasts
600: #Cannabis News and #Stocks on the Move; (CSE: $BRAX.C) (OTC: $BRAXF) (OTC:
$ERBB) (OTCQX: $AVCNF) (NASDAQ: $GNLN)
Delta, Kelowna, BC, August 27, 2021 (Invstoride, s.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/082721-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/08271BRAX-ERBB-AVCNF-GNLN.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Greenlane Holdings, Inc. (NASDAQ: GNLN), a global house of brands and
one of the largest sellers of premium cannabis accessories, child-resistant
packaging, and specialty vaporization products, announced that its stockholders have approved
the proposed merger with KushCo
Holdings, Inc., a premier provider of ancillary products and services to
the legal cannabis and CBD industries.
Over 99%
of the votes cast on the merger proposal were voted in favor of the
Transaction. Furthermore, each other proposal submitted to stockholders at
Greenlane’s annual meeting of stockholders was approved by the requisite vote.
The Company expects to file with the Securities and Exchange Commission a Form
8-K disclosing the final voting results.
Pursuant
to the terms of the merger agreement, KushCo will become a wholly owned
subsidiary of Greenlane in an all-stock, tax-free business combination. Under
the terms of the merger agreement, KushCo’s stockholders will receive shares of
Greenlane Class A common stock based on the final exchange ratio to be
determined as of the closing date in accordance with the terms of the merger
agreement.
Avicanna Inc. (OTCQX: AVCNF), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
plant-derived cannabinoid-based products, announced that, through its majority-owned
Colombian subsidiary Santa Marta Golden Hemp S.A.S. (“SMGH”), it has completed
its first commercial export of 20 kg of high CBD full spectrum psychoactive
cannabis extracts (the “Cannabis Extracts”) to Brazil in connection with the
previously announced three (3) year master supply agreement that SMGH executed
with a leading Brazilian pharmaceutical in July, 2021.
This marks the 11th country to which
Avicanna has successfully completed export of Aureus-branded products in what
stands as a demonstration of the Company’s capabilities, innovation, and
regulatory expertise. This export also validates the emergence of the global
cannabinoid sector with reliance on quality, traceability and sustainability
that Avicanna’s Aureus products offer.
With a forecasted total market size
of approximately USD $9 billion by 2021, Brazil is expected to be one of the
biggest cannabis markets globally and the largest in Latin America,
particularly for medicinal cannabis products. The Cannabis Extracts will be
used in the production of several products which will be registered and
commercialized in Brazil through RDC 327/19 that regulates manufacturing,
registration, importation and dispensing of cannabis-derived products.
Lucas Nosiglia, President of
Avicanna LATAM, commented: “This export represents a key milestone for our team
and a validation of our capabilities as we continue to lead the way with our
products and have now entered our 11th country with the Aureus brand. The
export to Brazil also confirms the regulatory pathway and acts as a proof of
concept in the largest market in South America where we aim to establish
long-lasting supply relationships with our Brazilian pharmaceutical partners.”
American
Green
(OTC: ERBB) announced that it will be expanding its
E-commerce presence by launching on Groupon.com. American Green’s premium CBD and Hemp
products will be able to be purchased with vouchers located on the Groupon.com
platform beginning next month (September 2021).
The company is excited to add sales from Groupon as another revenue
stream and hopes to echo or exceed the success it is currently enjoying
following its launch on Amazon.com.
David G. Gwyther, American
Green’s president, said, “We are
extremely excited to offer our CBD products on Groupon.com There are very few e-commerce outlets that
sell CBD direct to consumers, and Groupon is by far the largest and most
successful platform. Groupon has over 24
million customers nationwide. Consumers
throughout the country will now have direct access to all of our CBD and Hemp
products on Groupon.com.”
“American Green is always looking
for innovative ways to introduce its CBD and Hemp products to new prospects and
new marketplaces. Groupon is perfectly aligned with our goals with respect to
pioneering new ideas that drive rapid growth in e-commerce environments,” said
Kevin Davis, VP President of Sales for American Green.
The American Green offers will be
optimized and marketed under Groupon's proprietary methods which include but
are not limited to: flash sale offers, remarketing campaigns, utilization of
additional channels (such as the Groupon app and partner websites) and other
online advertising channels.
Braxia
Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a medical research company with
clinics providing innovative ketamine treatments for persons with depression
and related disorders, announced that Braxia Scientific's clinical
research and development team will commence a randomized clinical trial (RCT)
using psilocybin.
"This will be the broadest
study of its kind," said Dr. Joshua Rosenblat, the trial's principal
investigator and medical director of the Canadian Rapid Treatment Centre of
Excellence Inc. (CRTCE), a wholly owned subsidiary of Braxia Scientific.
"Whereas most other
treatment-resistant depression (TRD) studies limit participation to patients
that have not found relief from a maximum of five other potential remedies, our
research will not have an upper limit, and will even include patients that have
endured dozens of unsuccessful medical trials, including ketamine and
electroconvulsive therapy.
"By including everyone with
more than two failed medical trials, we are increasing the degree to which the
results can be applied to a larger population, making our findings much
stronger. Furthermore, we will have less exclusion criteria and are even
including patients with bipolar depression – a huge first for the field – or
comorbid disorders, which were excluded in psilocybin studies done by other
companies."
Braxia Scientific CEO Dr. Roger
McIntyre added, "Integrating psilocybin provides immense opportunity for
benefit for those dealing with treatment-resistant depression. Unfortunately,
over one-third of the more than 300 million people suffering with depression
worldwide fail to adequately respond to currently approved treatments, and thus
the TRD market is very large and disproportionately dominates the majority of
mental health services."
The study will demonstrate that the
Company can effectively conduct a randomized controlled trial using
psychedelic-assisted therapy. This will enable the Company to build the
infrastructure for future studies and future clinical care, while also
compiling efficacy data and providing the opportunity to evaluate the therapist
training program launched at the end of June 2021.
This program run by the Braxia
Institute, the Company's training centre focused on advancing psychiatric
clinical practice and health services of ketamine and psychedelic treatment
therapy, has already cultivated a multi-disciplinary group of 20 therapists
from diverse psychiatry and psychotherapy backgrounds to implement safe and
effective psilocybin-assisted therapy for patients with depression.
Investor ideas reminds all listeners to read our
disclaimers and disclosures on the Investorideas.com website and that this
podcast is not an endorsement to buy products or services or securities.
Investors are reminded all investment involves risk and possible loss of
investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
Potcasts is now
a certified word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes
podcasts and columns : Crypto
Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast
, Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye
Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment